"The results showed that total error is reduced by about half, and outliers, where results are more than 20 per cent different from the reference value, are reduced by 90 per cent."
MICHAEL NOBLE, EXACSYS
PA has had an article dedicated to its healthcare developments in the FT Magazine. The article looks at how PA has developed a new diagnostic technology which improves the accuracy of mass-market blood tests to detect glucose levels in diabetics, for example.
The article explains that PA created a simple and effective solution which includes a “control sample” of the substance being tested within the diagnostic kit. The article gives an example of a blood sugar kit which tests a known reference solution of glucose at the same time as measuring the glucose in the patient's sample.
Michael Noble of Exacsys, a subsidiary of PA that develops improvements in diagnostic accuracy, explains: "We evaluated the performance of our live calibration in a clinical setting using blood samples from 160 patients with diabetes, with and without our correction technique. The results showed that total error is reduced by about half, and outliers, where results are more than 20 per cent different from the reference value, are reduced by 90 per cent."
The article reveals that the blood glucose test will be developed for a few more years before it reaches the market and that another likely application of the technology will test blood cholesterol levels.